Sun Pharma Advanced Research Company Ltd
- P/E
- 3.7x
- 52-week range
- 108 – 289
- ROE
- 281%
- ROCE
- 165%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. The Company’s other programs include Sezaby for the treatment of neonatal seizures, Vodobatinib for the treatment of neurodegenerative disorders (SCC-138), Vibozilimod for the treatment of autoimmune disorders (SCD-044), SCD-153 for the treatment of alopecia areata, SBO-154 for multiple cancer indications and SCO-155 for treatment of cancer. SBO-154 is an anti MUC1 ADC being developed for multiple tumor types expressing MUC1.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Sun Pharma Advanced Research Company Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)3.7 against a typical 34.3: cheaper than most peers (1st = cheapest).3rd of 220
- Sales growth+300% against a typical +15.6% from a year earlier.7th of 197
- Share price, 3 months−12.2% against a typical 0%.157th of 200
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by Acuite- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Acuite | ACUITE AA- | Stable | 6 Feb 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 6 Feb 2026 | New rating | ACUITE AA- | — | Acuite | ₹ 600 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 2 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the quarter and half year ended September 30, 2026 |
| 10 Aug 2026 | Financial Results | To consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 |
| 18 May 2026 | Financial Results | To consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026 |
| 9 Feb 2026 | Financial Results | To consider and approve the Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2025 |
| 14 Jan 2026 | Fund Raising | To consider Fund Raising through Preferential Allotment |
| 10 Nov 2025 | Financial Results | Sun Pharma Advanced Research Company Limited has informed the exchange about Board Meeting to be held on 10-Nov-2025 to inter-alia consider and approve the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2025 |
| 4 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 |
| Expenses | 113 | 116 | 124 | 112 | 117 | 89 | 81 | 62 | 74 | 65 | 80 | 74 |
| Operating Profit | −91 | −103 | −108 | −95 | −104 | −74 | −54 | −52 | −66 | −57 | 1,773 | −34 |
| OPM % | −432% | −740% | −649% | −566% | −808% | −499% | −198% | −543% | −838% | −673% | 96% | −86% |
| Other Income | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 | 0 | −12 | 2 | 24 |
| Interest | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 | 12 | 8 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Profit before tax | −86 | −100 | −107 | −97 | −108 | −80 | −61 | −52 | −76 | −81 | 1,761 | −21 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −86 | −100 | −107 | −97 | −108 | −80 | −61 | −52 | −76 | −81 | 1,761 | −21 |
| EPS in Rs | −2.66 | −3.07 | −3.29 | −2.98 | −3.32 | −2.46 | −1.88 | −1.6 | −2.34 | −2.48 | 54.26 | −0.65 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 28%
- 5 Years
- 49%
- 3 Years
- 99%
- TTM
- 2,856%
- 10 Years
- 38%
- 5 Years
- 65%
- 3 Years
- 108%
- TTM
- 631%
- 10 Years
- −6%
- 5 Years
- −7%
- 3 Years
- −4%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sun Pharma Advanced Research Company Ltd | ₹ 183.00 | — | 3.7x | — | 281% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 36.6x | 5.3x | 0% | 0% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 94.3x | 14.8x | 0% | 0% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 75.8x | 20x | 0% | 0% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.7x | 4.2x | 0% | 0% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 26.6x | 3.2x | 0% | 0% |
Management
- Anilkumar Raghavan
- Chief Executive Officer
- Anup Rathi
- Chief Financial Officer
- Kajal Kiran Damania
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.